Insecticides India Ltd Q2 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/plf7g0d5mlfcrpk9cci0sa2p.pdf

Key Takeaways


Season & Demand Environment

Aggarwal: "some prices or like the products have touched the bottom actually, which I have never seen in the last 20, 25 years of my experience. Going below this is almost impossible."

Premiumization & Product Strategy

Aggarwal: "We are trying to create our monopoly — monopoly in the sense that by bringing the new patented compounds, by making the new patented products. So the focus is now moving into that direction."

Margins & Profitability

Aggarwal: "from INR102 crores in the complete full year, we have bagged the profit of INR111 crores this year, actually in the half year itself."

Kaeros Acquisition & B2B

Aggarwal: "I was never keen to give it to Insecticides India and wanted to establish a new company. But when I had the plans to establish a big business, so there was a guidance that this should be done under Insecticides India itself."

Biologicals & Future Bets

Aggarwal: "We are focusing a lot on biologicals because I believe that biologicals is the future. And in future, all the technologies are going to run parallelly."

Brand & Competitive Positioning

Aggarwal: "The idea is we have created a large following for the Tractor Brand and people have developed their trust... Now we have to take it to the next level so that we can make Tractor Brand bigger so that nobody has questions while selecting a product because if it is a Tractor Brand, they should say yes."

Guidance & Commitments

CommitmentSpecificsTimeline
Top-line recoveryLarge part of the 10% Kharif shortfall to be recovered; "there will be some growth" in FY25 but 15% guidance is difficultFY25 full year
H2 growthGrowth expected in both top line and bottom line; "I'll not say that there will be a decline"H2 FY25
Rabi season strengthVery, very strong Rabi season expected on full reservoirs and ample moistureRabi season
International businessWill cross last year's achievement; order book already full to match last year's salesFY25
New product launches6-7 total launches in H2, including Torry Super and one more expected to reach Maharatna statusH2 FY25
Exclusive Nissan product launchRegistration expected November-December, certificate in 2-3 months, launch around MarchMarch 2025
Biologicals plantNew plant planned on 7-acre site; R&D team expandedNo date given
Profitability directionExpected to increase as company moves further into patented compoundsNo date given

Key Metrics

MetricQ2 FY25
Revenue from operations₹627 cr, compared to ₹696 cr in Q2 FY24
EBITDA₹90 cr, up 9% YoY from ₹82 cr
EBITDA margin14.4%, compared to 11.8% in Q2 FY24
PAT₹61 cr, up 16% YoY
H1 FY25 revenue from operations₹1,284 cr
H1 FY25 EBITDA₹128 cr
H1 FY25 EBITDA margin12.5%
H1 FY25 PAT₹111 cr, up ~34% YoY; exceeded full-year FY24 PAT of ₹102 cr
Maharatna products volume growth~10% YoY, despite sales returns
Generic products volume degrowth~13% YoY
Overall price decline~10% YoY
Sales returns booked in Q2₹35–40 cr, majorly from herbicides
Expected additional sales returns in Q3up to ₹10–15 cr of insecticide
Premium products share of B2C sales68%, generics at 32%
B2C sales share84% of total revenue; B2B 14%; exports 2%
Product segment mixInsecticide 61%, herbicide 21%, fungicide 15%, others 4%
FY25 top-line growth guidance15% growth target; management indicated maintaining it may be difficult
Industry volume growth estimate~4–5% (management estimate, not confirmed)
Upcoming product launches in H2 FY256–7 launches, including Torry Super; 4 launching in November